LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research


Neutrolis is a preclinical drug discovery company focused on researching new potential treatment options for inflammatory diseases where uncontrolled neutrophilic inflammation may be implicated, such as lupus and sepsis. Neutrophils are the predominant white blood cells present during acute inflammation. When patients are unable to regulate this inflammatory process, it can lead to worsening of disease. Using its proprietary genetic technology platform, Neutrolis is developing therapeutics with the goal of neutralizing excessive neutrophilic inflammation, as well as companion diagnostics to identify patients who are most likely to benefit from such therapeutics. 

  • Abdul Hakkim Rahamathullah, PhD Founder & CEO
  • Tobias Fuchs, PhD Founder & CSO
  • Danika Khong, PhD Lead Scientist